Baseimmune

Baseimmune is a pioneering biotech company specializing in antigen discovery and vaccine development. Located in London, this discovery stage venture utilizes a proprietary computational platform to understand pathogen evolution, allowing them to design cross-protective vaccines with broader coverage. Baseimmune holds a unique technological approach, where it addresses emerging and highly complex pathogens that have been unsuccessful with traditional vaccine development procedures. The company, founded in 2019, uses this innovative technology not only to combat existing diseases but also to adequately prepare for those that may arise due to pathogen mutation.

The company is powered by a team of experts in vaccine and software development, ensuring a scientific and tech-driven approach towards vaccine creation. At the company's core is its proprietary AI platform, which models pathogen evolution and immune responses to create future-proof vaccines. After its inception at the Jenner Institute University of Oxford, the founders have successfully led the company in accelerating the discovery of novel and cross-protective vaccines. Notably, Baseimmune’s portfolio includes two human vaccines against Malaria and a pancoronavirus vaccine, and a veterinary vaccine against African Swine Fever, all of which are currently under rigorous testing.

Investing interest in Baseimmune rests upon its state-of-the-art approach towards vaccination, concentrating on multi-target and gene-agnostic antigen selection. Its technology's ability to provide broader coverage that remains effective despite pathogen mutation presents a solid case for its burgeoning importance to global health security. The company provides a bold response to complex and emerging pathogens that traditional approaches have failed to tackle successfully. With a highly talented team and strong future prospects, Baseimmune is prominently positioned to revolutionize the landscape of vaccine development.

Connect